Technical Analysis for FNCH - Finch Therapeutics Group, Inc.

Grade Last Price % Change Price Change
F 11.45 -2.05% -0.24
FNCH closed up 820.47 percent on Friday, October 4, 2024, on 9 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. The bulls were able to push the stock to a new 52-week high.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup -2.05%
Crossed Above 20 DMA Bullish -2.05%
Crossed Above 200 DMA Bullish -2.05%
Crossed Above 50 DMA Bullish -2.05%
MACD Bullish Centerline Cross Bullish -2.05%
New 52 Week Closing High Bullish -2.05%
New Uptrend Bullish -2.05%
New 52 Week High Strength -2.05%
Wide Bands Range Expansion -2.05%
Above Upper BB Strength -2.05%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 18 hours ago
Down 2 % about 18 hours ago
Gilligan's Island Bearish Entry about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 1% about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Finch Therapeutics Group, Inc. Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Autoimmune Disease Infection Specialty Drugs Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Autism Spectrum Disorder Chronic Hepatitis B Virus Clostridioides Difficile Treatment Of Autism Spectrum Disorder University Of Minnesota

Is FNCH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.2
52 Week Low 0.8
Average Volume 73,768
200-Day Moving Average 3.22
50-Day Moving Average 2.10
20-Day Moving Average 1.89
10-Day Moving Average 2.39
Average True Range 1.00
RSI (14) 92.55
ADX 27.53
+DI 82.54
-DI 3.67
Chandelier Exit (Long, 3 ATRs) 9.19
Chandelier Exit (Short, 3 ATRs) 3.81
Upper Bollinger Bands 6.40
Lower Bollinger Band -2.61
Percent B (%b) 1.59
BandWidth 475.20
MACD Line 0.66
MACD Signal Line -0.03
MACD Histogram 0.6824
Fundamentals Value
Market Cap 18.77 Million
Num Shares 1.61 Million
EPS -61.48
Price-to-Earnings (P/E) Ratio -0.19
Price-to-Sales 35.61
Price-to-Book 0.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.46
Resistance 3 (R3) 12.54 12.37 12.33
Resistance 2 (R2) 12.37 12.18 12.33 12.28
Resistance 1 (R1) 12.03 12.05 11.95 11.95 12.24
Pivot Point 11.86 11.86 11.82 11.82 11.86
Support 1 (S1) 11.52 11.67 11.44 11.44 11.14
Support 2 (S2) 11.35 11.54 11.31 11.10
Support 3 (S3) 11.01 11.35 11.05
Support 4 (S4) 10.93